romiplostim

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Isolated Chemotherapy-induced Thrombocytopenia

Conditions

Isolated Chemotherapy-induced Thrombocytopenia

Trial Timeline

Jan 30, 2014 → Nov 13, 2023

NCT ID

NCT02052882

About romiplostim

romiplostim is a phase 2 stage product being developed by Amgen for Isolated Chemotherapy-induced Thrombocytopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT02052882. Target conditions include Isolated Chemotherapy-induced Thrombocytopenia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04673266	Phase 2	Active	Dec 14, 2020	Dec 1, 2026	Lymphoma Patients
NCT04478227	Phase 1	Completed	Aug 18, 2020	Jan 18, 2024	Bone Marrow Failure Disorders
NCT04478123	Phase 2	Completed	Jul 14, 2020	Jun 8, 2023	Multiple Myeloma
NCT03362177	Phase 3	Completed	Sep 30, 2019	Jan 9, 2025	Chemotherapy-induced Thrombocytopenia
NCT03343847	Phase 3	Withdrawn	Jan 27, 2018	Jul 17, 2021	Chemotherapy-induced Thrombocytopenia
NCT02279173	Phase 3	Completed	Dec 10, 2014	Aug 8, 2019	Immune Thrombocytopenia
NCT02052882	Phase 2	Completed	Jan 30, 2014	Nov 13, 2023	Isolated Chemotherapy-induced Thrombocytopenia
NCT01516619	Phase 2	Completed	Nov 1, 2011	Nov 1, 2012	Non-Hodgkin Lymphoma
NCT01143038	Phase 2	Completed	Nov 30, 2010	Dec 26, 2013	Idiopathic Thrombocytopenic Purpura
NCT01071954	Phase 3	Completed	Dec 30, 2009	Jan 12, 2017	Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP
NCT00907478	Approved	Completed	Aug 11, 2009	Jan 14, 2014	Thrombocytopenia
NCT00303472	Phase 2	Completed	Feb 1, 2006	May 1, 2008	Thrombocytopenia
NCT00508820	Phase 3	Completed	Feb 1, 2005	Mar 1, 2011	Idiopathic Thrombocytopenic Purpura
NCT00116688	Phase 3	Completed	Aug 1, 2004	Jan 1, 2010	Thrombocytopenia
NCT00117143	Phase 1/2	Completed	Dec 2, 2002	Jul 19, 2004	Thrombocytopenic Purpura

Competing Products

4 competing products in Isolated Chemotherapy-induced Thrombocytopenia

See all competitors

Product	Company	Stage	Hype Score
olmesartan medoxomil + hydrochlorothiazide, if necessary + nitrendipine + hydrochlorothiazide, if necessary	Daiichi Sankyo	Phase 3	77
Sprifermin (AS902330) 10 mcg + Sprifermin (AS902330) 30 mcg + Sprifermin (AS902330) 100 mcg	Merck	Phase 2	52
Rebif®	Merck	Phase 3	77
6R-BH4	BioMarin Pharmaceutical	Phase 2	49

Other Products from Amgen